To better understand how CREBBP/EP300 HAT inhibition leads to transcriptional changes in ER+ breast cancer cells, we performed ATAC-seq and H3K27 acetyl ChIP-seq upon treatment of MCF7 cells with CPI-1612. Here, EP300 is linked to breast cancer.